Melbourne, Australia, 29 March 2017: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), a molecular diagnostics company focused on cancer risk assessment, announced today an agreement with Dale Coyne Racing driver Ms. Pippa Mann to promote BREVAGenplus®, the Company’s first-in-class, clinically validated risk assessment test for sporadic breast cancer. The partnership is reflective of the Company’s continuation of its U.S. focused marketing program for BREVAGenplus, with Mann serving for a second consecutive term as the product’s ambassador and spokesperson.
Mann is one of only nine female athletes to ever compete in the “Indy 500” and the only female driver to start in the race over the past four consecutive years. In addition to her role with Genetic Technologies, Mann is partnering with Susan G. Komen®, the world’s largest breast cancer organisation, which funds more breast cancer research than any other non-profit, outside of the U.S. government, while providing screening, education, treatment and psychosocial support programs. In 2016, Mann was honoured as one of Komen’s More Than Pink™ heroes in support of the organisations Bold Goal – to reduce the current number of breast cancer deaths in the U.S. by half, by 2026.
“We are excited to continue this outstanding partnership with Pippa. She is truly dedicated to leveraging her platform as a world-class athlete to impact women’s health and shares our passion for the integral role BREVAGenplus can play as a breast cancer risk assessment and preventative treatment management tool,” commented Eutillio Buccilli, Executive Director and Chief Executive Officer of Genetic Technologies.
Key partnership activities this year will include the BREVAGenplus logo represented on Mann’s #63 Dale Coyne Racing car and promotional apparel. Mann will also participate at select BREVAGenplus oriented events and other promotional activities over the course of 2017. The 101st running of the Indianapolis 500 on May 28, 2017 will serve as the official launch of this year’s partnership program. The “Indy 500” is the largest single day sporting event in the world and offers important promotional opportunities during the month long lead-up to the race, which includes 12 days of on-track activities and hospitality event participation.
“I’m thrilled to welcome back Genetic Technologies as a partner with Dale Coyne Racing and proud to represent the BREVAGenplus brand. I’m excited to do my part in helping women and healthcare providers learn about the test, and highlight how important it can be in determining individual breast healthcare plans and personal medical maintenance,” commented Pippa Mann.